Filtern
Volltext vorhanden
- nein (1) (entfernen)
Gehört zur Bibliographie
- ja (1)
Erscheinungsjahr
- 2014 (1)
Dokumenttyp
Sprache
- Englisch (1) (entfernen)
Schlagworte
- lymphoma (1)
Institut
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (1) (entfernen)
Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma (CTCL) (1). Most patients initially respond well to standard therapy, but advanced MF is often treatment refractory. Thus, a combination of the available treatment options is an important strategy. Total skin electron beam radiation (TSEB) is effective in MF, with a complete remission rate of up to 90% in the early stages. However, in patients with more advanced stages, remission rates are considerably lower (2, 3). Denileukin diftitox (DD) (Ontak®) is a recombinant fusion protein of the receptor-binding domain of interleukin (IL)-2 and the enzymatic and translocation domains of diphtheria toxin (4). It targets the alpha-subunit of the IL-2-receptor (CD25). There are no reports on this combination therapy in MF.